GLP-1 Agonist Drugs Could Prevent 34,000 Heart Attacks and Strokes Annually

Healthline, New Delhi, September 2024: Recent research indicates that glucagon-like peptide-1 (GLP-1) receptor agonist drugs, such as Ozempic and Mounjaro, could prevent up to 34,000 heart attacks and strokes annually in the U.S. These medications, traditionally used for diabetes and obesity, have demonstrated cardiovascular benefits in previous trials for individuals with established heart conditions. However, new findings from Dandelion Health suggest that GLP-1 receptor agonists may also reduce cardiovascular risks for those with mild to moderate cardiovascular disease (CVD), expanding the potential user base to millions. Using predictive AI, the company discovered that patients taking GLP-1 agonists could experience cardiovascular benefits in less than two years. “Our study shows a significant reduction in cardiovascular risk for patients initiating GLP-1 treatment,” stated Nick Gossen, Head of Growth at Dandelion Health. While promising, the study has yet to undergo peer review. Cardiologist Chad S. Weldy, MD, PhD, from Stanford Medicine, remarked, “The leap to using GLP-1 agonists for primary prevention remains challenging, but the potential benefits are clear.” More research is needed to confirm these findings before widespread use of GLP-1 agonists for cardiovascular prevention.